BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23337370)

  • 1. Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?
    Roggenbuck D; Bogdanos D; Conrad K
    J Crohns Colitis; 2013 Aug; 7(7):e273-4. PubMed ID: 23337370
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Dr. Roggenbuck et al.'s letter.
    Stöcker W; Probst C; Komorowski L
    J Crohns Colitis; 2013 Aug; 7(7):e275-6. PubMed ID: 23466410
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
    Bogdanos DP; Rigopoulou EI; Smyk DS; Roggenbuck D; Reinhold D; Forbes A; Laass MW; Conrad K
    Autoimmun Rev; 2011 Dec; 11(2):143-8. PubMed ID: 21983481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
    Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
    Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological studies in inflammatory bowel disease: how important are they?
    Papp M; Lakatos PL
    Curr Opin Gastroenterol; 2014 Jul; 30(4):359-64. PubMed ID: 24811052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
    Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
    J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases.
    Colombel JF; Reumaux D; Duthilleul P; Noël LH; Gower-Rousseau C; Paris JC; Cortot A
    Gastroenterol Clin Biol; 1992; 16(8-9):656-60. PubMed ID: 1426820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
    Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
    Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Kossa K; Coulthart A; Ives CT; Pusey CD; Hodgson HJ
    Eur J Gastroenterol Hepatol; 1995 Aug; 7(8):783-9. PubMed ID: 7496870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease?
    Castellino F; Rosina F; Bansi DS; Bauducci M; Touscoz GA; Giorda L; Borghesio E; Bessone MP; Astegiano M; Musso A
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):859-64. PubMed ID: 8574718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives.
    Folwaczny C; Noehl N; Tschöp K; Endres SP; Heldwein W; Loeschke K; Fricke H
    Gastroenterology; 1997 Jul; 113(1):101-6. PubMed ID: 9207267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission.
    Lindgren S; Florén CH; Lindhagen T; Starck M; Stewenius J; Nässberger L
    Eur J Gastroenterol Hepatol; 1995 Jun; 7(6):563-8. PubMed ID: 7552641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role.
    Kull K; Salupere R; Uibo R; Ots M; Salupere V
    Hepatogastroenterology; 1998; 45(24):2132-7. PubMed ID: 9951879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.
    Roggenbuck D; Reinhold D; Baumgart DC; Schierack P; Conrad K; Laass MW
    Adv Clin Chem; 2016; 77():77-101. PubMed ID: 27717419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles IgM immunoreactivity in patients with inflammatory bowel disease.
    Balzola FA; Khan K; Pera A; Bonino F; Pounder RE; Wakefield AJ
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):378-82. PubMed ID: 9789132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
    Pavlidis P; Romanidou O; Roggenbuck D; Mytilinaiou MG; Al-Sulttan F; Liaskos C; Smyk DS; Koutsoumpas AL; Rigopoulou EI; Conrad K; Forbes A; Bogdanos DP
    Clin Dev Immunol; 2012; 2012():640835. PubMed ID: 23118780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.